Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Don't Miss our Black Friday Offers: Gil Blum has given his Hold rating due to a combination of factors observed in Fate Therapeutics’ recent clinical updates. The initial results for FT819 in a lupus ...

Fate Therapeutics (FATE) stock rallied 37% Monday on positive Phase 1 study data for its cell therapies FT819 and FT522. Read ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Wedbush ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 4.76% and 249.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

SAN DIEGO — SAN DIEGO — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $47.7 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 40 cents ...